Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Advertisement

Advertisement




Oct
05
Today In Oncology
FDA Approves First-Line Pirtobrutinib for CLL-SLL
Lung Cancer AI Model May Predict Pneumonitis Risk From Immunotherapy
FDA Approves Imlunestrant in Combination With Abemaciclib for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
Annual Report to the Nation: Progress Against Lung Cancer Drives Down Cancer Mortality
Are Narrower Negative Margins Linked to Higher Risk of DCIS Recurrence
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo